TerminatedPhase 2/3

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

Stopped: Futility, as a result of COVID-19 impact

United States13 participantsStarted 2019-08-21

Plain-language summary

The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients in a SBU Hospital ICU with rapid-AF (with ventricular rates \>100 bpm). * Patient screening will be conducted prior to patient or LAR consent. Exclusion Criteria: * Patients age \<18yrs; * Anticipated ICU stay \<11hrs; * Permanently paced heart rhythm; * Known 2nd or 3rd degree heart block; * Junctional rhythms; * Known pregnancy; * Known allergy to Dexmedetomidine; * Receiving Dexmedetomidine prior to study onset; * Non-intubated patients w/ Glasgow Coma Scale \<8; * Weight \>400lbs (protocol dosing restriction); * Untreated, symptomatic hypotension (SBP\<90mmHg); * Received amiodarone, lidocaine, or mexiletine w/in 4hrs prior to consent.

What they're measuring

Mean Systolic Blood Pressure

Timeframe: During Study Drug Infusion Period

Trial details

NCT IDNCT04042727

SponsorStony Brook University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31

Results submitted2024-04-10

View on ClinicalTrials.gov More Rapid Atrial Fibrillation trials